Diamyd Medical to present new genetic data at the ASIT summit in Boston, MA

Diamyd Medical is invited as a speaker at the 7[th] Antigen Specific Immune Tolerance summit to be held in Boston, MA, on March 18-20, 2024. CEO Ulf Hannelius will  present up-to-date HLA haplotype frequency data in Type 1 Diabetes collected as part of the ongoing precision medicine Phase 3 trial DIAGNODE-3. The antigen-specific immunotherapy Diamyd[®] was recently, as previously announced,  awarded Fast Track designation by the FDA.“Genetic data that have been collected from the ongoing Phase 3 trial confirm the previously estimated prevalence of the genetic patient population we are